Skip to main content
ELTX
NASDAQ Life Sciences

Elicio Therapeutics Reports Complete Responses with ELI-002 7P and Checkpoint Inhibitors in Pancreatic Cancer

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.33
Mkt Cap
$52.678M
52W Low
$2.66
52W High
$16
52W Position info
12% below low
Off High info
85% below high
Rel. Volume info
14× avg
Market data snapshot near publication time

ELTX is trading near its 52-week low of $2.66 (12% below the low) on elevated volume (14× avg).

Summary

Elicio Therapeutics reported preliminary clinical observations showing complete responses in three pancreatic cancer patients treated with ELI-002 7P followed by checkpoint inhibition, leading to plans for a new Phase 1 combination study.


Key Events · Product Development and Regulatory · ELTX

  • Preliminary Clinical Observations

    Three patients with metastatic mKRAS pancreatic cancer, who progressed on ELI-002 7P in the Phase 2 AMPLIFY-7P study, achieved 100% confirmed complete radiographic and metabolic responses after subsequent nivolumab-based therapy.

  • Rare Complete Responses

    Complete responses are rarely observed (0-8%) in metastatic pancreatic cancer, especially in microsatellite stable (MSS) / mismatch repair proficient (MMR-p) patients, which historically show limited response to immune checkpoint inhibitors.

  • Planned Phase 1 Study

    Elicio intends to initiate a Phase 1 study to evaluate ELI-002 7P in combination with checkpoint inhibition in first-line metastatic mKRAS pancreatic ductal adenocarcinoma (PDAC), subject to funding.

  • Strategic Pivot After Phase 2 Failure

    This news follows the recent announcement on June 15, 2026, that ELI-002 7P failed to meet its primary endpoint in the Phase 2 AMPLIFY-7P study, providing a new potential development pathway for the lead candidate.


Analysis · ELTX · Life Sciences

This filing provides a potential path forward for Elicio's lead candidate, ELI-002 7P, after its recent Phase 2 failure. While preliminary, the observation of complete responses in three patients with metastatic pancreatic cancer, a notoriously difficult-to-treat disease, when ELI-002 7P was followed by checkpoint inhibition, offers a new development strategy. This could be crucial for the company, which is operating under a 'going concern' warning and has an active ATM program to raise capital. The planned Phase 1 study, though subject to funding, aims to validate this combination, potentially shifting the investment thesis from a failed monotherapy to a promising combination approach.

How filings like this one have moved

In the 30 days to Nov 5, 2026, 43.4% of the 1274 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.16%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ELTX was trading at $2.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $52.7M. The 52-week trading range was $2.66 to $16.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELTX - Latest Insights

ELTX
Nov 05, 2026, 4:14 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.41
Real-time Price: $1.38 info
Change: -$0.0249 (-2%) info
Market Cap: $37.928M info
ELTX
Nov 05, 2026, 4:12 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $1.38 info
Change: -$0.0249 (-2%) info
Market Cap: $37.928M info
ELTX
Oct 23, 2026, 9:00 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.78
Real-time Price: $1.38 info
Change: -$0.3999 (-22%) info
Market Cap: $37.928M info
ELTX
Aug 13, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.10
Real-time Price: $1.38 info
Change: -$1.72 (-56%) info
Market Cap: $37.928M info
ELTX
Jul 06, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.26
Real-time Price: $1.38 info
Change: -$1.88 (-58%) info
Market Cap: $37.928M info